Italian CDMO and API supplier Olon has presented a two-year, €30 million plan to expand its Settimo Torinese Biotech Hub near Turin. This focuses on microbial fermentation and is claimed to have “some of the most extensive know-how” on the subject in Europe”. The plan focuses on therapeutic peptides based on Olon’s expertise in the development of rDNA peptides and proteins.
Lonza has completed the expansion of a multi-purpose. kilogram-scale HPAPI manufacturing suite at its main site in Visp, Switzerland. This adds development and manufacturing capacity for ADC payloads, “supporting the entire development and manufacturing pipeline from feasibility studies to commercial supply”.
The proposed acquisition of US-based Snapdragon Chemistry by the Chinese CDMO Asymchem Laboratories has been abandoned. The two firms were unable to agree mitigation terms that would satisfy the US Treasury’s Committee on Foreign Investment in the United States (CFIUS).
SK Capital Partners have made an investment in VanDeMark Chemical in partnership with Comvest Partners, which has been a co-owner since 2019. The amount involved was not disclosed but VanDeMark said that this would “serve as a catalyst for a new strategic direction as the company seeks to deepen and expand its presence in fine chemistries for the global life science market”.
Evotec has bought the German manufacturing operations of Japan’s Central Glass for a nominal €1. The deal is subject to customary closing conditions and is expected to close on 1 November. The business will be renamed Evotec Drug Substance (Germany).
SK Pharmteco affiliate Ampac Fine Chemicals (AFC) has added a complex molecule chemistry and engineering centre at its main site in Rancho Cordova, California. “This expands upon our core technologies such as energetic chemistry, high potency, chromatography and continuous processing”, said Dr John Jacobsen, executive director of R&D.